Indeed, samples overexpressing the three TFs (AR, HOXC6 and NKX2-2) together accounted for up to 80% of metastatic prostate cancer samples in the Taylor data set, suggesting that the combined inhibition of AR, HOXC6 and NKX2-2 may represent a more effective strategy to develop prostate cancer therapies. The gene discussed is NKX2-2; the disease is prostate carcinoma.